Title:GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery
Volume: 19
Issue: 16
Author(s): Manveen K. Gupta*Neelakantan T. Vasudevan*
Affiliation:
- Department of Molecular Cardiology, Cleveland Clinic, Cleveland, Ohio 44106,United States
- Thermalin Inc, Cleveland, Ohio 44106,United States
Keywords:
GPCRs, Insulin Signaling, Diabetes, Cross-talk, Drug Discovery, RTKs, IRs.
Abstract: Type 2 diabetes is a major health issue worldwide with complex metabolic and endocrine abnormalities.
Hyperglycemia, defects in insulin secretion and insulin resistance are classic features of
type 2 diabetes. Insulin signaling regulates metabolic homeostasis by regulating glucose and lipid turnover
in the liver, skeletal muscle and adipose tissue. Major treatment modalities for diabetes include the
drugs from the class of sulfonyl urea, Insulin, GLP-1 agonists, SGLT2 inhibitors, DPP-IV inhibitors and
Thiazolidinediones. Emerging antidiabetic therapeutics also include classes of drugs targeting GPCRs in
the liver, adipose tissue and skeletal muscle. Interestingly, recent research highlights several shared intermediates
between insulin and GPCR signaling cascades opening potential novel avenues for diabetic
drug discovery.